Ibnsina Pharma (CAI:ISPH) FFO


CAI:ISPH Ibnsina Pharma CAI:ISPH
85 GF Score
Price E£11.60
GF Value E£10.47
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma FFO?

FFO (Funds from operations) only applies to REITs.

CAI:ISPH
85GF Score
Ibnsina Pharma CAI:ISPH
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£11.60 is trading 10.8% above its estimated GF Value™ of E£10.47. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • FFO:
  • GF Value™: E£10.47 vs. price of E£11.60 (10.8% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score

Get the complete analysis for CAI:ISPH

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£11.60
Price
E£10.47
GF Value